Abstract 9916: Prognostic Value of Simultaneous Analysis With Myocardial Flow Reserve and Right Ventricular Strain by Hybrid ¹³ N-ammonia Positron Emission Tomography/Magnetic Resonance Imaging in Coronary Artery Disease

Abstract

Introduction: Myocardial flow reserve (MFR) derived from 13 N-ammonia positron emission tomography (PET) is used to predict adverse cardiac events in the patients with coronary artery disease (CAD). Right ventricular (RV) strain measured by magnetic resonance imaging (MRI) is used to evaluate RV function. This study aimed to evaluate the prognostic value of combined MFR and RV strain measured by hybrid 13 N-ammonia PET/MRI in patients with CAD. Methods: Sixty-one patients who underwent 13 N-ammonia PET/MRI were enrolled. MFR was calculated from dynamic acquisition of 13 N-ammonia PET under vasodilator stress with intravenous injection of adenosine. RV global longitudinal strain (GLS) was measured by wall motion tracking techniques in cine-mode MRI. The end points were defined as a composite of all-cause death, myocardial infarction, sustained ventricular arrhythmia, hospitalization due to decompensated heart failure, and revascularization. Results: At a follow-up of 2.8 ± 1.9 years, 21 events occurred. Kaplan-Meier analysis showed that the event-free rate was significantly lower in the group with MFR < 1.80 than that with MFR ≥ 1.80 (P < 0.001, Figure a). Additionally, the event-free rate was significantly lower in the group with RVGLS > –18.22% than that with RVGLS ≤ –18.22% (P = 0.025, Figure b). After dividing the patients into four groups by the median MFR and the median RVGLS, the event-free rate was lowest in the combined group of MFR < 1.80 and RVGLS > -18.22% than any other groups (P < 0.001, Figure c). In the Cox proportional hazard analysis, MFR and RVGLS were independent predictors of cardiac adverse events in the patients with CAD. Conclusion: The simultaneous assessment of MFR and RV strain by 13 N-ammonia PET/MRI revealed the feasibility of precise risk stratification for cardiac events in patients with CAD.